In almost all reported cases, MLL and the partner gene lie in a 5 0 -3 0 orientation allowing for transcription of the fusion product. We describe two cases of lymphoid malignancy, one an acute leukaemia of B-cell origin and the other a precursor-T leukaemia/lymphoma both of which showed fusion of the MLL and TOB2 genes in a tail-tail orientation. To the best of our knowledge this is the first description of recurrent involvement of the MLL gene in a rearrangement, which does not permit transcription. We discuss the implications of this finding for malignancy.
Patient 9878, a 14-month-old baby girl, presented with a history of lethargy and fever and a mass on the right side of her forehead. She had suffered from chronic ill health since birth. On physical examination generalized lymphodenopathy and hepatosplenomegaly were seen, whereas skin biopsy showed Langerhans Cell Histiocytosis (LCH). A diagnosis of common/pre-B acute lymphoblastic leukaemia (ALL) was made with a white blood cell count of 23.6 Â 10 9 /l. Therapy was commenced according to UK ALL 2003 Regimen A, which was changed to Regimen C on day 15 when she was discovered to have a rearrangement of the MLL gene. The patient entered remission but had a bone marrow relapse with refractory ALL 15 months after diagnosis. She was started on the UK ALL R3 protocol but relapsed again 2 months later. A third line of chemotherapy was abandoned for clinical reasons and in view of the poor prognosis cytogenetics. The patient died shortly afterwards.
Interphase fluorescence in situ hybridization (FISH) at diagnosis showed that 54% of nuclei had a split signal for the MLL gene (MLL breakapart probe, Abbott Diagnostics, Maidenhead, Berkshire, UK). This had increased to 94% of nuclei in the relapse sample. The karyotype at diagnosis was 46,XX,t(7;22;11)(q11;q13;q23),del(8)(p21p23) and at relapse was 47,XX,t(7;22;11)(q11;q13;q23), þ mar. It was most likely that the marker of the relapse sample was the chromosome 8 with a deleted short arm seen at diagnosis, while there had also been a duplication of the normal copy of chromosome 8. There were no karyograms available for comparison to confirm this interpretation.
Patient 10067 was an 11-year-old girl who presented after a 1 week shortness of breath. Chest X-ray (CXR) and tomography (CT) confirmed the presence of a mediastinal mass with significant pleural effusion. Bone marrow analysis confirmed precursor T-ALL was made (CD2, CD5, CD7, TDT, cytoplasmic CD3 and CD79a positive) with a white blood cell of 15.8 Â 10 9 /l. Treatment was commenced after UKALL 2003 regimen B. At this time, the rearrangement of the MLL gene had not been discovered. At day 28, the mediastinal mass was smaller but still significant. Treatment was intensified and switched to an individualized regimen. However at 8 months, prior to a fully matched sibling transplant, the mass remained: by 8 months post transplant the mediastinum was normal. The child was eventually removed from the ALL trial because of the persistent mediastinal mass, which was more indicative of a T-cell non-Hodgkin's lymphoma. Currently, she remains well, 49 months from diagnosis and 42 months after bone marrow transplantion.
FISH of the diagnostic sample with the same probe showed that 81% of the interphase nuclei had a split signal for the MLL gene. The diagnostic karyotype was 46,XX,der(7)t(7;14) (q3?;q?3),t(11;22)(q23;q13). Probes to 7q31 (D7S522) Â 2 (Abbott Diagnostics) and to TRB@ (7q34) Â 1 (DakoCytomation, Glostrup, Denmark) indicated that the breakpoint on the der(7) was between them, whereas probes to BCL11B (BAC clones: RP11-145P8 and RP11-15E14, Sanger Centre, Cambridge, UK) (14q32) Â 3 and IGH@ (Abbott Diagnostics) (14q32) Â 3 indicated that the breakpoint on the chromosome 14 component of the der(7) was proximal to them. A probe to CDKN2A (p16(9p21) Abbott Diagnostics) showed a bi-allelic deletion of this gene in 89% of interphase nuclei.
FISH mapping was carried out to identify the breakpoint on chromosome 22 in both patients. BAC probes RP11-110H11 (start 40.09 Mb, finish 40.28 Mb) and RP11-420C16 (start 40.52 Mb, finish 40.67 Mb) (Sanger Centre, Cambridge, UK) map to the long arm of chromosome 22. They hybridized to both the der(11) and the der(22) on abnormal metaphases in both patients as well as to the normal copy of chromosome 22, localizing the breakpoint on chromosome 22 to the TOB2 gene.
Molecular studies were carried out according to the availability of suitable material. Long distance inverse PCR was performed on the two cases to clone the translocation breakpoints. Sequencing analysis revealed a fusion between MLL and TOB2, which showed the genes in opposite orientations in both cases (Figures 1a and b) . In case 9878, the genomic breakpoint locations within MLL and TOB2 were in intron 9 (117860091 bp) and intron 1 (40164431 bp), respectively (Figure 1b) . Case 10067 showed different genomic breakpoints in intron 12 of MLL (117864870 bp) and intron 1 of TOB2 at 40169882 bp (Figure 1b) . RT-PCR was carried out to detect the transcript in cDNA from patient 9878 but failed to amplify the fusion cDNA sequence, demonstrating that the fusion of MLL and TOB2 was not transcribed.
The expression levels of MLL and TOB2 were analysed in the diagnostic and relapse samples of case 9878 by qRT-PCR and compared to a panel of control samples using a standard t-test. Both samples showed significantly lower levels for MLL expression compared with the MLL rearranged controls (0.61 vs 5.31-fold average) (Po0.02) (Figure 1c) . Case 9878 also exhibited reduced TOB2 expression compared with the other samples (0.53 vs 0.95-fold average) (Po0.02) (Figure 1c) .
The TOB2 gene located at the cytogenetic band 22q13.2-13.31 is the transducer of ERBB2 and belongs to the TOB family of antiproliferative proteins, which are involved in the regulation of cell-cycle progression from the G0/G1 to S phases. It is 13 536 bases in size and its protein contains 344 amino acids. By gene expression profiling in a mouse model system, which involved two cell lines one with wild type and the other with disrupted MLL, TOB was one of the top 40 over-expressed genes in the MLL knockout cells. Thus, it seems that the absence of MLL protein is linked to the expression of a variety of candidate genes that might be important for leukaemogenesis. A reduction in MLL gene dose (haploinsufficiency) appeared to mimic the MLL knockout situation. 3 The antithesis to this is that MLL fusions are not always tumourogenic. Generated MLL-ENL fusions in translocator mice caused myeloid neoplasias in stem cells or progenitors, whereas no tumours arose when the translocation was restricted to the B-cell compartment although the fusion mRNA was expressed. 4 A report of a variant t(8;21) acute myeloid leukaemia in which a new clone characterized by a MLL rearrangement t(11;11)(q13;q23) developed within 16 months of diagnosis involving fusion with the ARHGEF17 gene extends this finding into the clinic. The sample showed no morphological suspicion of a secondary malignancy. 5 The case most directly comparable to our findings showed a fusion between BCL9L (also in 11q23) and MLL, which deleted a chromosomal region of B300 kb, and fused MLL tail-tail with the 3 0 non-translated region of BCL9L. Thus, as in our case, no functional structural protein was produced. 6 Our two cases both had karyotypes, which involved the long arm of chromosome 7, but with different breakpoints. In case 9878, the three-way translocation between chromosomes 7, 11 and 22 appeared to involve a break at 7q11. This child had LCH at diagnosis. There is evidence that both the LCH and the Letters to the Editor leukaemic cells in the same individual may have a common clonal origin, demonstrated by identical rearrangements for the T-cell g receptor gene. 7 Although reports of the cytogenetics of LCH are few and far between, a single reported karyotype had a breakpoint in the long arm of chromosome 7 at (7q11) in a recurrent translocation with 12p13. 8 In conclusion, we report two cases of lymphoid malignancy with different immunophenotypes, each of which showed fusion of the MLL and TOB2 genes in a tail-tail rearrangement, with no transcription of a fusion product. The expression of both genes was reduced in both the diagnostic and relapse samples of one patient. Without functional studies, which were impossible to perform, because of lack of suitable material, these are no more than interesting observations. If the MLL gene involvement was responsible for the leukaemia or the lymphoma, it may well have been functioning through its haploinsufficiency, rather than by the more common method of production of a fusion gene protein. There is evidence that some genes when expressed at half normal levels cannot fully suppress tumour growth. 9 Emerging reports show the multiple ways in which MLL is represented in malignancy. It would be surprising if this oncogene was not central to the leukaemic process in one of the cases we report here that showed an identical disease progression to that seen in MLL rearranged infant leukaemia. Letters to the Editor
